Abstract
In lieu of large bioequivalence studies and exposing healthy postmenopausal women to additional drug exposure for elagolix coadministered with hormonal add-back therapy, physiologically based pharmacokinetic (PBPK) modeling was used with in vitro dissolution data to test for virtual bioequivalence. For endometriosis, elagolix is approved at doses of 150 mg once daily and 200 mg twice daily as a tablet. As a combination therapy, two individual tablets, consisting of an elagolix tablet and an estradiol/norethindrone acetate 1/0.5 mg (E2/NETA) tablet, were utilized in Phase 3 endometriosis trials. However, the commercial combination drug products consist of a morning capsule (containing an elagolix tablet and E2/NETA tablet as a fixed-dose combination capsule, AM capsule) and an evening capsule (consisting of an elagolix tablet, PM capsule). In vitro dissolution profiles were dissimilar for the tablet and capsule formulations; thus, in vivo bioequivalence studies or a bioequivalence waiver would have been required. To simulate virtual cross-over, bioequivalence trials, in vitro dissolution data was incorporated into a previously verified PBPK model. The updated PBPK model was externally validated using relevant bioequivalence study data. Based on results of the virtual bioequivalence simulations, the commercial drug product capsules met the bioequivalence criteria of 0.80–1.25 when compared to the reference tablets. This was a novel example where PBPK modeling was utilized along with in vitro dissolution data to demonstrate virtual bioequivalence in support of a regulatory bioequivalence waiver.
Graphical Abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis datasets), as well as other information (e.g., protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time, and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our–science/clinical–trials/clinical–trials–data–and–information–sharing/data–and–information–sharing–with–qualified–researchers.htm.
References
Loisios-Konstantinidis I, Cristofoletti R, Fotaki N, Turner DB, Dressman J. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. Case example: Naproxen. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2020;143:105170. https://doi.org/10.1016/j.ejps.2019.105170.
Pepin XJH, Parrott N, Dressman J, Delvadia P, Mitra A, Zhang X, et al. Current state and future expectations of translational modeling strategies to support drug product development, manufacturing changes and controls: a workshop summary report. J Pharm Sci. 2020. https://doi.org/10.1016/j.xphs.2020.04.021.
FDA. Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101720038-pdf Accessed August 9 2022. 2017.
FDA. Guidance for Industry. Dissolution testing of immediate release solid oral dosage forms. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-immediate-release-solid-oral-dosage-forms Accessed August 9 2022. 1997.
Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration’s Office of Clinical Pharmacology. J Pharm Sci. 2019;108(1):21–5. https://doi.org/10.1016/j.xphs.2018.10.033.
Basu S, Lien YTK, Vozmediano V, Schlender JF, Eissing T, Schmidt S, et al. Physiologically based pharmacokinetic modeling of monoclonal antibodies in pediatric populations using PK-Sim. Front Pharmacol. 2020;11:868. https://doi.org/10.3389/fphar.2020.00868.
Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences. 2014;57:300–21. https://doi.org/10.1016/j.ejps.2013.09.008.
Orilissa™ (elagolix) [United States package insert]. North Chicago, IL: AbbVie Inc.; 2018.
Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) [United States package insert]. North Chicago, IL: AbbVie Inc. ; 2020.
Elagolix multidiscipline review, US FDA Center for Drug Evaluation and Research. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213388Orig1s000MultidisciplineR.pdf. Accessed August 9, 2022.
Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–40. https://doi.org/10.1056/NEJMoa1904351.
Elagolix multidiscipline review, US FDA Center for Drug Evaluation and Research. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf. Accessed August 9, 2022.
AbbVie Inc. A phase 3 study to evaluate the safety and efficacy of elagolix in combination with estradiol/norethindrone acetate in subjects with moderate to severe endometriosis-associated pain. ClinicalTrials.gov identifier: NCT03213457 (M14-702). Last updated February 16, 2022. https://clinicaltrials.gov/ct2/show/NCT03213457. Accessed 9 Aug 2022
Chiney MS, Ng J, Gibbs JP, Shebley M. Quantitative assessment of elagolix enzyme-transporter interplay and drug-drug interactions using physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2020;59(5):617–27. https://doi.org/10.1007/s40262-019-00833-6.
Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, et al. Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet. 2020;59(3):297–309. https://doi.org/10.1007/s40262-019-00840-7.
Pade D, Jamei M, Rostami-Hodjegan A, Turner DB. Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon. Biopharm Drug Dispos. 2017;38(2):94–114. https://doi.org/10.1002/bdd.2072.
Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4 -methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008;51(23):7478–85. https://doi.org/10.1021/jm8006454.
Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, et al. Assessment of clinical drug-drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist. J Clin Pharmacol. 2020;60(12):1606–16. https://doi.org/10.1002/jcph.1689.
AbbVie Inc. A phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NBI-56418 in subjects with endometriosis. ClincialTrials.gov identifier: NCT00619866 (NBI-56418). Updated September 7, 2018. https://clinicaltrials.gov/ct2/show/NCT00619866. Accessed 9 Aug 2022
Fiolka T, Van Den Abeele J, Augustijns P, Arora S, Dressman J. Biorelevant two-stage in vitro testing for rDCS classification and in PBPK modeling-case example ritonavir. J Pharm Sci. 2020;109(8):2512–26. https://doi.org/10.1016/j.xphs.2020.04.023.
Acknowledgements
Medical writing support was provided by Stormy Koeniger, PhD, an AbbVie employee.
Funding
This work was funded by AbbVie. AbbVie contributed to the study design, research, interpretation of data, and the writing, review, and approval of this publication.
Author information
Authors and Affiliations
Contributions
DM, MJC, MS, and PM contributed to the conceptualization, methodology, and formal analysis of this work and writing of the manuscript. XS and TRJ contributed to the investigation, methodology, data analysis, and data curation for this work. All authors participated in the interpretation of data, final review, and approval of the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
All authors are current employees of AbbVie and may hold AbbVie stock or stock options.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mukherjee, D., Chen, MJ., Shao, X. et al. Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling. AAPS J 25, 30 (2023). https://doi.org/10.1208/s12248-023-00794-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/s12248-023-00794-6